简介:目的人类白细胞抗原B新等位基因核苷酸序列分析及确认。方法采用序列特异性寡核苷酸探针技术(SSO)对2015年中国造血干细胞捐献者资料库(CMDP)入库数据进行HLA常规检测,结果显示有1个磁珠反应异常,进一步选择多聚酶链反应-测序(PCR-SBT)分型发现1个与HLA-B*67相关的有1个碱基不匹配的等位基因,选择对应的组特异性引物对该等位基因进行2次分离式测序,确认突变的等位基因和突变位点。结果发现1个与HLA-B*67:01:01序列相近的新等位基因,实验结果表明在HLA-B*67:0:01第3外显子370位置G>A,其突变造成HLA-B*67:01:01氨基酸序列中100位的氨基端由甘氨酸(Gly)变成丝氨酸(Ser)。结论本次实验确认了1个新的HLA等位基因,2016年3月30日被世界卫生组织HLA因子命名委员会正式命名为HLA-B*67:07。
简介:TodeterminewhetherthepossessionofcertainHLA-DQA1alleleswasassociatedwiththeriskofdevelopingidiopathicdilatedcardiomyopathy(IDC)andtosubstantiatetheroleofanautoimmunologicpathogenesisinIDC.TypetheallelesofHLA-DQA1bypolymerasechainreactionwithsequence-specificprimers(PCR-SSP)techniquein38patientsofidiopathicdilatedcardiomyopathy(7womenand31men),agedfrom17to56yearsoldwithdiagnosisbeingaccordingtoWorldHealthOrganizationcriteria(IDCgroup),in50patientsofend-stageheartfailureofknownetiology(18womenand32men),withagesrangingfrom34to72(HFgroup),andinthecontrolgroupconsistingofpresumably100healthysubjects(39womenand61men)fromthehealthsurvey,agedfrom30to59yearsold.ThefrequencyofHLA-DQA1*0501intheDCMpatientswassignificantlyelevatedthanthatintheHFandthecontrolgroup.MolecularanalysisoftheDQA1genepolymorphismperformedinthethreesubgroupsshowsanincreasedfrequencyofDQA1*0501amongpatientswithlessEF.TheHFgroupcarriesahighfrequencyofHLA-DQA1*0301.AnincreasedfrequencyofDQA1*0201andDQA1*0103wasfoundinthecontrolgroup.HLA-DQA1*0501isanassociatedgeneofidiopathicdilatedcardiomyopathyandthepossessionofDQA1*0301maybeindicativeoftheknownetiologicheartfailure,suggestingthatthemechanismsinvolvedinthepathogenesisofIDCandotherwiseheartfailurearedifferent.ImmunologicabnormalitiesmaybeamajorcontributortothesusceptibilityofdevelopingofIDC.
简介:本研究建立可溶性人类白细胞抗原-Ⅰ类(sHLA-Ⅰ)检测方法,并探讨贮存血中sHLA-Ⅰ浓度变化的意义.采用ELISA双抗夹心法定量检测60例正常广东人血清中sHLA-Ⅰ水平和20例献血员成分血中sHLA-Ⅰ含量.结果表明:采用本技术时,可溶性HLA-Ⅰ最低检测限为2.84ng/ml,批内变异系数为5.80%,批间变异系数为9.00%,回收率≥98.57%,广东人sHLA-Ⅰ平均值为(699.54±360.10)ng/ml.贮存28天的RBC和随机供者血小板的sHLA-Ⅰ的浓度明显高于其它成分血,并且与成分血中残存的白细胞数和贮存时间有关.结论:用ELISA法检测可溶性HLA-Ⅰ灵敏、特异、稳定,在临床输血过程中可考虑选择性输注含有不同浓度可溶性HLA-Ⅰ的成分血.
简介:客观:在人的hepatocellular癌(HCC)在HLA医生表示上调查干扰素(IFN)的管理效果。方法:房间衬里的在4种HCC的HLA医生的表示,HHCC,SMMC-7721,BEL-7402,HCC-9204和一个正常的肝房间衬里QZG在被IFN-或IFN-的不同剂量刺激前后与immunohistochemicalABC和ELISA方法被检测。结果:仅仅SMMC-7721房间的小部分表示了另外的房间线的HLA医生,和所有是在有IFN-或IFN-的刺激前否定的HLA医生。HLA医生表示在刺激以后5根房间线在所有被提高,并且它与IFN的剂量被相关。QZG房间不比HCC房间明显。IFN-的效果比IFN-的更明显。结论:IFN能在HCC房间提高HLA医生表示。
简介:Analysisofthefrequencyofantigen-specificcytotoxicTlymphocytes(CTLs)exvivoislargelydependentontheuseofMHC/peptidetetramers.However,thelatterreagentshavenotbeenwidelyavailable,mostlikelybecauseoftheircostlyandtime-consumingproduction.InthisreportweutilizedaneconomicstrategytoconstructHLA/peptidetetramerswithrecombinantpeptide-linkedβ2microglobulin(β2m).TheHLA-A2-restricted,melanomaantigenMARTl-derivedpeptideMARTI27-35(AAGIGILTV)wasfusedtotheNterminusofhumanβ2mthrougha15-aminoacid(aa)-longlinkerbeforebeingrefoldedwiththerecombinantbiotinylatedHLA-A2heavychainectodomain.Theresulted2-component(2C)monomerwasthentetramerizedwithphycoerythin-labeledstreptavidin.Theexperimentalresultshowedthatthe2CHLA-A2/MARTI27-35monomerwasshowntobindtotheHLAclassⅠcomplex-specificmonoclonalantibodyW6/32andtheHLA-A2/MARTI27-35complex-specificsinglechainantibodyfragment(scFv)8.3,suggestingthecorrectnessofitsspecificity.Furthermore,the2CHLA-A2/MARTI27-35tetramerdetectedaspecificCD8^+TcellpopulationinHLA-A2-restrictedmelanomainfiltratinglymphocytesastheconventional3CHLA-A2/MARTI27-35tetramer.Theyieldof2CHLA-A2/MARTI27-35monomerwas2.5timesmorethanthatoftheconventional3Cmonomer.Takentogether,thesedataindicatethattheHLA-A2/MARTI27-35tetramercanbegeneratedconvenientlythroughtheuseofMARTI27-35peptide-β2mfusionproteins,whichcanfacilitatethemonitoringofHLA-A2-restricted,MARTl-specificCTLresponsesinpatientswithmelanoma.
简介:摘要目的探讨解决血小板输注无效的有效途径,改善血小板输注的临床效果。方法对42例各类血小板输注无效患者进行HLA抗体特异性分析。采用FCXM技术对20例各类血小板输注无效患者进行配合试验,选择HLA-I类位点3个以上抗原相合,输注适合的血小板并与22例各类血小板输注无效患者随机血小板输注进行临床观察。结果42例各类血小板输注无效患者中34例HLA-I抗体阳性,阳性率为80.9%。配合性血小板输注患者的24小时血小板上升均值高于随机血小板输注患者(P<0.05)。结论反复随机输注血小板易发生同种免疫反应,产生HLA抗体,导致血小板输注无效,建立者血小板供者资料库,采用FCXM技术交叉配型选择HLA相合或相容单一供体进行血小板输注,实现提高血小板输注治疗效果,是解决PTR的有效途径。
简介:RecentstudiessuggestthatMHCclassⅡgenetransfercouldstimulateprotectiveantitumorimmunity.WhetherxenogeneicMHCⅡtransfectedtumorcellshavetheseeffectisunknown.Inthisstudy,HLA-DR3αandβchaincDNAwereclonedbyRT-PCRfromhumanBlymphomaRajicelllineandconfirmedbyDNAsequencing.TherecombinantexpressingvectorswereconstructedbyinsertingtheαandβchaincDNAintoPCEP4/pLXSNvectorsrespectively.AftertransfectingbylipofectamineandselectingwithG418andHyg,theHLA-DR3transfectedmousemelanomaB16recombinantcloneswereobtained.Approximately59%ofthe
简介:利用HLA的设计思想对通信对抗仿真系统的体系结构进行分析,在此基础上建立了通信对抗仿真系统的系统结构框图,并对系统的各功能模块以及主体部分的设计实现进行了分析和研究。